Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong growth opportunities for Boston Scientific in innovative medtech therapies, supported by recently launched products and M&A and also contends that its Farapulse and Watchman products are “strong drivers of sales growth”, the analyst tells investors in a research note. Boston Scientific is also gaining share in Cardiology and expanding its presence in overseas markets, such as Japan, China and Europe, Argus adds.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Optimistic 2025 Outlook and Strong Innovation Drive Buy Rating for Boston Scientific
- Boston Scientific price target raised to $120 from $115 at Stifel
- Boston Scientific price target raised to $118 from $111 at Barclays
- Boston Scientific price target raised to $122 from $119 at Raymond James
- Boston Scientific price target raised to $120 from $110 at Truist